|
| The role of BCL2 family proteins in traditional Chinese medicine intervention for myocardial ischemia/reperfusion injury |
| Hits 346 Download times 192 Received:March 19, 2025 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2025.07.17 |
| Key Words
BCL2 family proteins;traditional Chinese medicine;ischemia-reperfusion injury |
| Author Name | Affiliation | E-mail | | LIU Dongyan | China Academy of Chinese Medical Sciences, Beijing 100700, China
Guangzhou Baiyunshan Pharmaceutical Holdings CO., LTD. Baiyunshan Pharmaceutical General Factory, Guangzhou 510515, China
Key Laboratory of Key Technology Research on Chemical Raw Materials and Preparations of Guangdong Province, Guangzhou 510515, China | | | XIE Zhoufan | Guangzhou Baiyunshan Pharmaceutical Holdings CO., LTD. Baiyunshan Pharmaceutical General Factory, Guangzhou 510515, China
Key Laboratory of Key Technology Research on Chemical Raw Materials and Preparations of Guangdong Province, Guangzhou 510515, China | | | XU Zejun | Guangzhou Baiyunshan Pharmaceutical Holdings CO., LTD. Baiyunshan Pharmaceutical General Factory, Guangzhou 510515, China
Jinan University, Guangzhou, 510632, China | | | ZHAO Haiyu | China Academy of Chinese Medical Sciences, Beijing 100700, China | | | LIAO Yiqiu | Guangzhou Baiyunshan Pharmaceutical Holdings CO., LTD. Baiyunshan Pharmaceutical General Factory, Guangzhou 510515, China
Key Laboratory of Key Technology Research on Chemical Raw Materials and Preparations of Guangdong Province, Guangzhou 510515, China | | | GUO Ruizhi | Guangzhou Baiyunshan Pharmaceutical Holdings CO., LTD. Baiyunshan Pharmaceutical General Factory, Guangzhou 510515, China
Key Laboratory of Key Technology Research on Chemical Raw Materials and Preparations of Guangdong Province, Guangzhou 510515, China | | | QIN Fei | Guangzhou Baiyunshan Pharmaceutical Holdings CO., LTD. Baiyunshan Pharmaceutical General Factory, Guangzhou 510515, China
Key Laboratory of Key Technology Research on Chemical Raw Materials and Preparations of Guangdong Province, Guangzhou 510515, China | | | WANG Jiansong | Guangzhou Baiyunshan Pharmaceutical Holdings CO., LTD. Baiyunshan Pharmaceutical General Factory, Guangzhou 510515, China
Key Laboratory of Key Technology Research on Chemical Raw Materials and Preparations of Guangdong Province, Guangzhou 510515, China | 105889@byszc.com | | BAO Yingxia | Guangzhou Baiyunshan Pharmaceutical Holdings CO., LTD. Baiyunshan Pharmaceutical General Factory, Guangzhou 510515, China
Key Laboratory of Key Technology Research on Chemical Raw Materials and Preparations of Guangdong Province, Guangzhou 510515, China | hongjun0420@vip.sina.com | | YANG Hongjun | China Academy of Chinese Medical Sciences, Beijing 100700, China | |
|
| Abstract
|
| Myocardial infarction（MI） and ischemia-reperfusion injury are significant factors leading to the death of patients with coronary heart disease. Although clinical interventions such as thrombolysis are routinely employed to treat MI，myocardial ischemia/reperfusion injury often occurs during ischemic episodes and subsequent blood flow restoration. Traditional Chinese medicine（TCM） has gained widespread application in myocardial protection against I/R due to its multi-target synergistic effects and favorable safety profile. However，the precise mechanisms underlying its therapeutic efficacy remain incompletely elucidated，hindering further exploration of TCM-based strategies for I/R myocardial protection. A pivotal approach to reducing mortality in MI or I/R patients involves targeting multiple signaling pathways to suppress B-cell lymphoma-2（BCL2） family protein-regulated mitochondrial outer membrane permeabilization（MOMP）-driven apoptosis and mitochondrial permeability transition pore（MPTP）-mediated necroptosis. Currently，neither conventional chemical drugs nor TCM agents have been conclusively identified to directly target BAK/BAX for I/R treatment. Exploring TCM compounds targeting BAK/BAX while leveraging their inherent multi-target synergistic properties may represent an effective strategy to advance TCM-based interventions for I/R. Therefore，addressing the lack of inhibitors targeting the key I/R molecule BAK/BAX and the limited efficacy of I/R treatments，this review discusses the role of BCL2 family proteins in CHM-mediated I/R protection and proposes a new strategy to identify CHMs that directly inhibit BAK/BAX proteins and formulate them based on traditional Chinese medicine theory，further leveraging the multi-target synergistic，efficacy-enhancing，and toxicity-reducing effects of CHMs for myocardial cell protection. |
|
|
|
|
|
|
|
